Publications by authors named "Marlene Da Vitoria Lobo"

Article Synopsis
  • Chemotherapy-induced neuropathic pain (CINP) is a significant issue for pediatric cancer survivors, and current pain treatments are not effective due to limited understanding of CINP mechanisms.
  • This study explores how cisplatin leads to neuroinflammation and increased pain sensitivity through nerve growth factor (NGF) interactions, particularly focusing on macrophage activity in the dorsal root ganglia (DRG).
  • The research findings suggest that targeting the NGF-TrkA signaling pathway in macrophages may offer new pain relief strategies for adults who survived childhood cancer.
View Article and Find Full Text PDF

Cisplatin-based chemotherapy is a common treatment for paediatric cancer. Unfortunately, cisplatin treatment causes neuropathic pain, a highly prevalent adverse health related complication in adult childhood cancer survivors. Due to minimal understanding of this condition, there are currently no condition tailored analgesics available.

View Article and Find Full Text PDF

Neuropathic pain, such as that seen in diabetes mellitus, results in part from central sensitisation in the dorsal horn. However, the mechanisms responsible for such sensitisation remain unclear. There is evidence that disturbances in the integrity of the spinal vascular network can be causative factors in the development of neuropathic pain.

View Article and Find Full Text PDF

The spinal cord, a compartment of the central nervous system, is made up of a number of architecturally distinct neural centers that influence an array of neurophysiological systems. The primary role of the spinal cord is the modulation of sensory and motor function by acting as a relay station between the periphery and the brain. Inherently these are considered as neural networks, however the functional dynamics of these tissues consist of a heterogenic population of cell types, all working in harmony to maintain physiological function.

View Article and Find Full Text PDF

Retinal and choroidal diseases are major causes of blindness and visual impairment in the developed world and on the rise due to an ageing population and diabetes epidemic. Standard of care is centred around blockade of vascular endothelial growth factor (VEGF), but despite having halved the number of patients losing sight, a high rate of patient non-response and loss of efficacy over time are key challenges. Dysregulation of vascular homoeostasis, coupled with fibrosis and inflammation, are major culprits driving sight-threatening eye diseases.

View Article and Find Full Text PDF